Esperion Therapeutics (ESPR) Goldman Sachs 45th Annual Global Healthcare Conference summary

Company overview and recent developments

• Focuses on life-saving drugs, primarily for cholesterol management, with plans to expand into other therapeutic areas.

• Bempedoic acid, a first-in-class LDL cholesterol-lowering drug, was approved in March 2020.

• CLEAR Outcomes study, a 14,000-patient trial, demonstrated significant efficacy and diversity in patient population.

• Recent label expansion now covers both primary and secondary prevention, greatly increasing the addressable market.

• Collaboration with large partners like Daiichi Sankyo and Otsuka supports global reach.

Market access, payer dynamics, and sales force

• Previous label restrictions limited market size and required extensive documentation for reimbursement.

• New label and outcomes data have led to improved payer acceptance and easier access for physicians.

• Over 10 payer wins since June 1, with some plans removing prior authorization requirements.

• Sales force of 150 representatives, supported by key account managers and reimbursement specialists, targets both primary care and cardiologists.

• Specialty pharmacy Aspen provides support for prior authorizations and patient access.

Financial position and commercial outlook

• Resolved litigation with Daiichi Sankyo, resulting in $125 million in cash and future royalties from a triple combination product.

• Ended the quarter with $226 million in cash, with an additional $25 million milestone expected soon.

• No immediate need for additional capital; focus is on addressing debt and achieving break-even.

• Commercial infrastructure is right-sized, with no significant expansion planned.

• Gross-to-net headwinds have improved, and further improvements are expected as volume grows.